NeuroOne appoints medtech exec Christopher Volker as COO; inducement plan expanded by 420,350 shares

NEUROONE MEDICAL TECHNOLOGIES Corp

Christopher Volker appointed COO effective Nov 10, 2023; formerly Head of Commercial Integration at Abbott and VP/GM International at Cardiovascular Systems.
Volker receives base salary of $288,000, 40% target bonus, and option to purchase 324,560 shares at $1.32 per share.
Inducement plan amended to increase reserved shares from 150,000 to 570,350 to attract qualified employees.
Option vests 25% after one year, then monthly over 36 months; accelerated vesting upon change in control.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher R. Volker

Chief Operating Officer

NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp

Effective: 2023-11-10
Filed: November 14, 2023, 6:59 PM ET

Christopher R. Volker, age 52, has been appointed as the Chief Operating Officer of the Company, effective on November 10, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher R. Volker was appointed as Chief Operating Officer at NEUROONE MEDICAL TECHNOLOGIES Corp.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Christopher R. Volker, age 52, has been appointed as the Chief Operating Officer of the Company, effective on November 10, 2023.

View on SEC.gov

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-087126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.